DB07268JNK1 inhibitor CAS# 929007-72-7 |
- JNK-IN-7
Catalog No.:BCC1672
CAS No.:1408064-71-0
- JNK-IN-8
Catalog No.:BCC1673
CAS No.:1410880-22-6
- CC-401 hydrochloride
Catalog No.:BCC1458
CAS No.:1438391-30-0
- AS 602801
Catalog No.:BCC1369
CAS No.:848344-36-5
- CC-930
Catalog No.:BCC1459
CAS No.:899805-25-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 929007-72-7 | SDF | Download SDF |
| PubChem ID | 16058637 | Appearance | Powder |
| Formula | C17H15N5O2 | M.Wt | 321.33 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 32 mg/mL (99.59 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[[2-(3-hydroxyanilino)pyrimidin-4-yl]amino]benzamide | ||
| SMILES | C1=CC=C(C(=C1)C(=O)N)NC2=NC(=NC=C2)NC3=CC(=CC=C3)O | ||
| Standard InChIKey | QHPKKGUGRGRSGA-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H15N5O2/c18-16(24)13-6-1-2-7-14(13)21-15-8-9-19-17(22-15)20-11-4-3-5-12(23)10-11/h1-10,23H,(H2,18,24)(H2,19,20,21,22) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM.In Vitro:DB07268 (Compound 2b) also inhibits CHK1, PAK4, AKT1, and ERK2 with IC50s of 0.82 μM, 5.5 μM, 15 μM, and 25 μM, respectively[1]. References: | |||||
DB07268 Dilution Calculator
DB07268 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1121 mL | 15.5603 mL | 31.1207 mL | 62.2413 mL | 77.8016 mL |
| 5 mM | 0.6224 mL | 3.1121 mL | 6.2241 mL | 12.4483 mL | 15.5603 mL |
| 10 mM | 0.3112 mL | 1.556 mL | 3.1121 mL | 6.2241 mL | 7.7802 mL |
| 50 mM | 0.0622 mL | 0.3112 mL | 0.6224 mL | 1.2448 mL | 1.556 mL |
| 100 mM | 0.0311 mL | 0.1556 mL | 0.3112 mL | 0.6224 mL | 0.778 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: 9 nM for JNK1
DB07268 is a JNK1 inhibitor. The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase family. Three JNK isoforms (JNK1, 2 and 3) have been identified. There is growing evidences indicating that activation of the JNK activity is involved in a number of human disease settings. Therefore, considerable efforts have been directed toward the identification of JNK inhibitors suitable for clinical development.
In vitro: The selectivity data of DB07268 against a panel of kinases has been tested. Results showed that DB07268 had some degree of selectivity over quite a few kinases with the exceptions of PLK, CHK1, and CK2. Although d DB07268 showed submicromolar potency against these three kinases, it still appeared to exhibit at least 70- to 90-fold greater potency against JNK1 than PLK, CHK1, and CK2 [1].
In vivo: Several analogs of DB07268 were profiled in vivo. These compounds had a range of exposure in rats and mice. Some had excellent brain penetration despite having poor rat pharmacokinetics, while others had a more balanced profile. Unfortunately, the most potent analog exhibited poor rat pk demonstrated by a short half-life, low oral absorption and poor brain penetration. One DB07268 analog likely exhibited modest rat pk with low clearance and decent oral absorption. This analog also showed modest brain penetration [1].
Clinical trial: So far, no clinical study has been reported.
References:
[1] Liu M,Wang S,Clampit JE,Gum RJ,Haasch DL,Rondinone CM,Trevillyan JM,Abad-Zapatero C,Fry EH,Sham HL,Liu G. Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett.2007 Feb 1;17(3):668-72. Epub 2006 Nov 2.
[2] Romain Nol, Youseung Shin, Xinyi Song, Yuanjun He, Marcel Koenig, Weimin Chen, Yuan Yuan Ling, Li Lin, Claudia H. Ruiz, Phil LoGrasso, Michael D. Cameron, Derek R. Duckett, Theodore M. Kamenecka. Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-Jun N-terminal kinase inhibitors.Bioorg Med Chem Lett. 2011 May 1; 21(9): 2732–2735.
- PF-03716556
Catalog No.:BCC2084
CAS No.:928774-43-0
- IRAK inhibitor 2
Catalog No.:BCC1655
CAS No.:928333-30-6
- AS 1892802
Catalog No.:BCC6335
CAS No.:928320-12-1
- MN 64
Catalog No.:BCC6489
CAS No.:92831-11-3
- Boc-D-Asp-OBzl
Catalog No.:BCC3370
CAS No.:92828-64-3
- 3-Chloro-1-(4-octylphenyl)-propanone
Catalog No.:BCN2249
CAS No.:928165-59-7
- Tenacissoside F
Catalog No.:BCN4472
CAS No.:928151-78-4
- Alisol O
Catalog No.:BCN3362
CAS No.:928148-51-0
- Golvatinib (E7050)
Catalog No.:BCC4423
CAS No.:928037-13-2
- RAF265
Catalog No.:BCC3677
CAS No.:927880-90-8
- DPNI-caged-GABA
Catalog No.:BCC5957
CAS No.:927866-58-8
- KC7F2
Catalog No.:BCC2434
CAS No.:927822-86-4
- Pracinostat (SB939)
Catalog No.:BCC2152
CAS No.:929016-96-6
- GSK461364
Catalog No.:BCC3788
CAS No.:929095-18-1
- 7-Oxo-ganoderic acid Z
Catalog No.:BCN7973
CAS No.:929248-72-6
- LUF 6283
Catalog No.:BCC6318
CAS No.:92933-48-7
- Fmoc-Tyr-OH
Catalog No.:BCC3562
CAS No.:92954-90-0
- Bavisant
Catalog No.:BCC1402
CAS No.:929622-08-2
- Bavisant dihydrochloride
Catalog No.:BCC1403
CAS No.:929622-09-3
- Sessilifoline A
Catalog No.:BCN4473
CAS No.:929637-35-4
- Cucumegastigmane I
Catalog No.:BCN4474
CAS No.:929881-46-9
- SGI-110
Catalog No.:BCC2221
CAS No.:929901-49-5
- 3,4-Dimethoxybenzyl Alcohol
Catalog No.:BCN2721
CAS No.:93-03-8
- 3,4-Dimethoxybenzoic acid
Catalog No.:BCN4475
CAS No.:93-07-2
